Iga Jancewicz

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 14

Top Venues

Cancer immunology, immunotherapy : CII

IUBMB life

Cancers

The oncologist

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie Jul 01 2019

Poland

Junior assistant :: Department of Molecular and Translational Oncology

Education History

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

Poland

PHD

Warsaw University of Technology

Poland

MSC :: Faculty of Chemistry

Warsaw University of Life Sciences

Poland

BSC :: Faculty of Hirticulture, Biotechnology and Landscape Architecture

Publications

Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
Correction to: New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
Correction to: New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
Correction to: New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (9) (2024)
Iga Jancewicz, Magdalena Śmiech, Magdalena Winiarska, Radoslaw Zagożdżon, Pawel Wisniewski
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo. Cancer immunology, immunotherapy : CII 73 (2) (2024)
Iga Jancewicz, Joanna Szarkowska, Ryszard Konopinski, Malgorzata Stachowiak, Monika Swiatek, Katarzyna Blachnio, Szymon Kubala, Paulina Oksinska, Pawel Cwiek, Natalia Rusetska, Agnieszka Tupalska, Natalia Zeber-Lubecka, Ewa Grabowska, Bianka Swiderska, Agata Malinowska, Michal Mikula, Beata Jagielska, Jan Walewski, Janusz A Siedlecki, Tomasz J Sarnowski, Sergiusz Markowicz, Elzbieta A Sarnowska
PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells. Cancers 13 (16) (2021)
Michal Szymanski, Natalia Rusetska, Iga Jancewicz, Alicja Armatowska, Marcin Ligaj, Alicja Chrzan, Kinga Hińcza-Nowak, Artur Kowalik, Pawel Mika, Maciej Kisiel, Jakub Zolnierek, Joanna Kosior, Tomasz Demkow, Janusz A Siedlecki, Tomasz J Sarnowski, Elzbieta A Sarnowska
Succinate Dehydrogenase-Deficient Renal Cancer Featuring Fructose-1,6-Biphosphatase Loss, Pyruvate Kinase M2 Overexpression, and SWI/SNF Chromatin Remodeling Complex Aberrations: A Rare Case Report. The oncologist 26 (9) (2021)
Malgorzata Stachowiak, Michal Szymanski, Anna Ornoch, Iga Jancewicz, Natalia Rusetska, Alicja Chrzan, Tomasz Demkow, Janusz A Siedlecki, Tomasz J Sarnowski, Elzbieta A Sarnowska
SWI/SNF chromatin remodeling complex and glucose metabolism are deregulated in advanced bladder cancer. IUBMB life 72 (6) (2020)
Monika Swiatek, Iga Jancewicz, Jakkapong Kluebsoongnoen, Renata Zub, Anna Maassen, Szymon Kubala, Apinunt Udomkit, Janusz A Siedlecki, Tomasz J Sarnowski, Elzbieta A Sarnowska
Various forms of HIF-1α protein characterize the clear cell renal cell carcinoma cell lines. IUBMB life 72 (6) (2020)

Iga Jancewicz.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Iga Jancewicz